Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

AbstractBackgroundTranscutaneous vagus nerve stimulation (VNS) showed early evidence of efficacy for the gait treatment of Parkinson's disease (PD).ObjectivesProviding data on neurophysiological and clinical effects of transauricular VNS (taVNS).MethodsTen patients with recording deep brain stimulation (DBS) have been enrolled in a within participant design pilot study, double‐blind crossover sham‐controlled trial of taVNS. Subthalamic local field potentials (β band power), Unified Parkinson's Disease Rating Scales (UPDRS), and a digital timed‐up‐and‐go test (TUG) were measured and compared with real versus sham taVNS during medication‐off/DBS‐OFF condition.ResultsThe left taVNS induced a reduction of the total β power in the contralateral (ie, right) subthalamic nucleus and an improvement of TUG time, speed, and variability. The taVNS‐induced β reduction correlated with the improvement of gait speed. No major clinical changes were observed at UPDRS.ConclusionstaVNS is a promising strategy for the management of PD gait, deserving prospective trials of chronic neuromodulation. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

More information Original publication

DOI

10.1002/mds.29690

Type

Journal article

Publisher

Wiley

Publication Date

2024-02-01T00:00:00+00:00

Volume

39

Pages

424 - 428

Total pages

4